Peptide skepticism on TikTok: Is the "not worth it" take fair?

What did @charitykface actually say?

She called AOD 9604 "more trouble than it's worth" and, more bluntly, "a scam," based on her personal experience using seven or eight vials purchased from a gray-market vendor in 2023. Her main complaints were practical: the peptide gelled during reconstitution, results were nonexistent or too subtle to attribute confidently, and she was also on tirzepatide the whole time. She does leave a small door open, saying it "may" be a stall breaker and that the scale moved slightly on two occasions, but she won't credit AOD for that.

The honest framing here matters. She is clear this is opinion, not clinical testimony. She was roughly 50 to 60 pounds from her goal weight, had uterine fibroids causing abdominal distension, and was actively using a GLP-1/GIP receptor agonist. That is a chaotic backdrop for evaluating any single compound, and she acknowledges it, which is more self-aware than most peptide content on this platform.

Does the science back this up?

On the scam question: partially, yes. AOD 9604 is a synthetic analog of the C-terminal fragment of human growth hormone (hGH), specifically amino acids 177 to 191. The theoretical mechanism, stimulating fat breakdown and inhibiting lipogenesis without the insulin-resistance effects of full hGH, is real and not invented. The problem is that the human trial record is thin and largely disappointing.

The most cited clinical work comes from Metabolic Pharmaceuticals, which ran Phase 2 trials in the early 2000s. A 2004 trial (Heffernan et al., published in the context of Metabolic's clinical development program) showed modest weight loss in obese adults over 12 weeks, but effects were small and did not hold up robustly across subsequent trials. Metabolic's Phase 3 program was ultimately discontinued. The peptide is GRAS-designated for food use in the U.S. but has never received FDA approval as a drug. Rodent data showing lipolytic activity (Ng et al., 2000, Journal of Endocrinology) does not translate cleanly to human outcomes, which is a recurring problem in peptide research.

The reconstitution issue she describes, the gelling, is a documented solubility problem. AOD 9604 has poor solubility in standard bacteriostatic water, and the workaround involving dilute acetic acid (AA water) is a community-developed solution with no standardized protocol behind it.

What did they get wrong (or right)?

She got the core frustration right: AOD's human evidence is weak, and the reconstitution headaches are real. The "results were not like resulting" critique lands, because the controlled human data does not support dramatic fat-loss outcomes.

Where she is imprecise: attributing zero results partly to the peptide when she was simultaneously on tirzepatide, managing a fibroid-affected abdomen, and not at a stable body composition baseline is not a clean experimental condition. You cannot reliably isolate AOD's effect in that scenario. She actually acknowledges this, which is good, but then still calls it a scam. That conclusion is stronger than her evidence allows.

She is also conflating two separate critiques: poor efficacy and poor usability. Both may be true, but they are different problems. A compound can be difficult to reconstitute and still have a measurable pharmacological effect, or it can be easy to use and do nothing. Calling something a scam based on both together, without separating them, is sloppy reasoning even if the conclusion might be defensible.

What should you actually know?

AOD 9604 occupies an awkward regulatory and scientific space. It has a plausible mechanism, some animal-model support, and early human trial data that showed a signal but not a convincing one. The clinical development program was shelved. It is not approved by the FDA as a therapeutic drug. Peptide compounds sourced from gray-market or compounding sources carry additional uncertainty around purity, concentration accuracy, and sterility, which the creator implicitly flags by noting hers "gelled up" even from a well-regarded vendor.

The stall-breaker use case she mentions is entirely anecdotal in the community. There is no published controlled trial testing AOD 9604 specifically for weight-loss plateaus in people on GLP-1 agonists. Anyone using it for that purpose is self-experimenting without a clinical evidence base to stand on.

• AOD 9604 is not the same as full hGH and does not carry the same risks, but it also does not carry the same clinical validation.
• Reconstitution in dilute acetic acid is a workaround, not a tested standardized method endorsed by any regulatory body.
• Concurrent tirzepatide use makes any personal outcome from AOD uninterpretable as evidence for or against the peptide.
• Gray-market peptides are not subject to the same manufacturing oversight as regulated pharmaceuticals, regardless of third-party testing claims.